What should I look for in CJC-1295 + Ipamorelin Blend sourcing and quality?

Acceptable CJC-1295 + Ipamorelin Blend certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching Variable, endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

What is the evidence base for CJC-1295 + Ipamorelin Blend?

CJC-1295 + Ipamorelin Blend's evidence base sits at off-label clinical use; mechanistic studies. The references on this page summarise 2 primary publications supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The longevity / hallmarks of aging interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

How does CJC-1295 + Ipamorelin Blend's half-life affect dosing?

CJC-1295 + Ipamorelin Blend has a plasma half-life of Mixed, which is moderate, supporting once-daily dosing in most protocols. The receptor occupancy curve under 1-3x daily subq dosing at 100 mcg CJC + 200 mcg ipamorelin per dose explains the typical onset timeline for healthspan and biological-age endpoints.

What class of compound is CJC-1295 + Ipamorelin Blend?

CJC-1295 + Ipamorelin Blend is classified as a GHRH + GHRP combination. Within this class, alternative names and analogues include CJC/Ipa, GH-Releasing Stack. The class-level pharmacology shapes both the clinical applications and the safety profile; the longevity / hallmarks of aging literature treats CJC-1295 + Ipamorelin Blend alongside its class peers when evaluating relative merits.

What are the safety considerations for CJC-1295 + Ipamorelin Blend?

Lowest-side-effect profile of GH-releasing stacks. Site reactions and mild flushing possible. For healthspan and biological-age use, additional considerations: baseline labs appropriate to the targeted system, mid-cycle re-check at 4–6 weeks, and end-of-cycle full re-evaluation. CJC-1295 + Ipamorelin Blend's Mixed pharmacokinetic profile and subq administration route influence the side-effect profile in predictable ways.

Home/ Compounds/ CJC-1295 + Ipamorelin Blend

CJC-1295 + Ipamorelin Blend

Longevity

For users tracking biological age and healthspan-relevant biomarkers, CJC-1295 + Ipamorelin Blend sits within a multi-component longevity framework spanning hallmarks-of-aging from cellular (telomere, senescence, mitochondrial) through integrative (inflammaging, nutrient sensing). The canonical GHRH + GHRP stack — synergistic GH release with minimal off-target effects on cortisol or prolactin. Cycle-based dosing over 8-12 weeks with pre-post biomarker tracking is the longevity-research convention.

Longevity / Hallmarks of Aging Applications

Cellular ReprogrammingEpigenetic AgingAutophagy InductionGenomic StabilityHallmarks of Aging

Key Takeaways

Longevity lens: CJC-1295 + Ipamorelin Blend maps to specific hallmarks-of-aging endpoints rather than to acute clinical markers.
Mechanism: CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor.
Healthspan biomarkers: epigenetic age, telomere length, inflammatory markers, metabolic flexibility - all tracked across pre-post cycles.
Longevity protocol: cycle-based 100 mcg CJC + 200 mcg ipamorelin 1-3x daily subq dosing; 8-12 week cycles favoured over continuous administration.
Longevity stack partners: Epithalon, Thymalin, NAD+.

Longevity / Hallmarks of Aging Mechanism

For longevity-relevant evaluation, CJC-1295 + Ipamorelin Blend's mechanism is examined against the hallmarks of aging rather than against acute clinical endpoints. CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor. The two pathways converge on the same somatotroph but use independent receptors, producing a multiplicative rather than additive GH pulse. Ipamorelin's selectivity avoids the cortisol/prolactin elevation seen with GHRP-6 and GHRP-2. The subsections below address the hallmarks mapping, cellular reprogramming layer, healthspan markers, and dosing-pattern conventions in longevity research.

Cellular reprogramming and gene expression

Where CJC-1295 + Ipamorelin Blend has measurable effects on transcriptional programmes, the direction of effect tends to be toward younger phenotypes rather than away from them. This signature — partial reversal of age-associated expression changes — is what distinguishes a true longevity-relevant compound from a symptomatic one. The signal strength varies, but the direction is what longevity researchers track.

Cycle-based versus continuous dosing

CJC-1295 + Ipamorelin Blend's longevity protocol is compatible with either cycle-based or continuous dosing depending on the broader stack. The longevity-research convention favours pulsatile and periodic interventions over indefinite continuous administration, on the principle that hormetic stimulation outperforms sustained agonism for systems-biology-relevant endpoints.

Mapping to the hallmarks of aging

CJC-1295 + Ipamorelin Blend's longevity relevance is best evaluated by mapping its mechanism to the hallmarks-of-aging framework. CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor. The two pathways converge on the same somatotroph but use independent receptors, producing a multiplicative rather than additive GH pulse. Ipamorelin's selectivity avoids the cortisol/prolactin elevation seen with GHRP-6 and GHRP-2. This places its dominant contribution in the integrative hallmarks (systemic and inflammatory) layer of the framework, with secondary effects on adjacent hallmarks that combine to produce the broader healthspan-relevant phenotype.

Longevity / Hallmarks of Aging Applications

Hallmarks of Aging

Hallmarks of Aging maps to one of the hallmarks of aging and is one of the dimensions on which CJC-1295 + Ipamorelin Blend is evaluated in the longevity literature. Effect size on biomarkers varies across studies; the consistent finding is direction-of-effect rather than dramatic magnitude.

Genomic Stability

For genomic stability as a longevity-relevant endpoint, CJC-1295 + Ipamorelin Blend is typically run in cycle-based protocols with paired pre-post biomarker measurement. Epigenetic age tracking, telomere length, and inflammatory panels are the standard outcome measures.

Autophagy Induction

CJC-1295 + Ipamorelin Blend's contribution to autophagy induction as a longevity dimension is incremental rather than dramatic, consistent with the broader picture of healthspan-relevant peptides. The compound is best understood as one layer in a multi-component longevity protocol.

mTOR Modulation

mTOR Modulation maps to one of the hallmarks of aging and is one of the dimensions on which CJC-1295 + Ipamorelin Blend is evaluated in the longevity literature. Effect size on biomarkers varies across studies; the consistent finding is direction-of-effect rather than dramatic magnitude.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	100 mcg CJC + 200 mcg ipamorelin	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	60 mcg CJC + 200 mcg ipamorelin	4–6 weeks initial cycle
Longevity focus	SubQ	100 mcg CJC + 200 mcg ipamorelin	1-3x daily SubQ
Maintenance phase	SubQ	70 mcg CJC + 200 mcg ipamorelin	Ongoing with periodic pauses

Dose timing for CJC-1295 + Ipamorelin Blend is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses. Fasted dosing produces stronger GH pulses; meal-paired dosing blunts the response.

Stacking

CJC-1295 + Ipamorelin Blend stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from longevity researchers.

CJC-1295 + Ipamorelin Blend + Epithalon: Identified by Khavinson in St. Pairs naturally with CJC-1295 + Ipamorelin Blend's mechanism in longevity / hallmarks of aging protocols.
CJC-1295 + Ipamorelin Blend + Thymalin: Influences T-cell maturation and immune function. Pairs naturally with CJC-1295 + Ipamorelin Blend's mechanism in longevity / hallmarks of aging protocols.
CJC-1295 + Ipamorelin Blend + NAD+: Coenzyme for over 500 enzymatic reactions including oxidative phosphorylation, glycolysis, fatty acid β-oxidation, and the citric acid cycle. Pairs naturally with CJC-1295 + Ipamorelin Blend's mechanism in longevity / hallmarks of aging protocols.
CJC-1295 + Ipamorelin Blend + MOTS-c: Translocates to the nucleus under metabolic stress and activates AMPK signalling. Pairs naturally with CJC-1295 + Ipamorelin Blend's mechanism in longevity / hallmarks of aging protocols.

Safety & Regulatory Status

WADA: Both components banned (S2) FDA: Unapproved Research: Off-label clinical use; mechanistic studies

Lowest-side-effect profile of GH-releasing stacks. Site reactions and mild flushing possible.

Lens-specific safety considerations for longevity / hallmarks of aging use of CJC-1295 + Ipamorelin Blend: Lowest-side-effect profile of GH-releasing stacks. Site reactions and mild flushing possible. Additional longevity / hallmarks of aging monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Ipamorelin selective GH secretagogue

PMID 9849822

CJC-1295 + Ipamorelin Blend vs Related Peptides

Compound	Profile	Onset	Best For
CJC-1295 + Ipamorelin Blend	GHRH + GHRP combination	Mixed	Longevity
Epithalon	Pineal-derived tetrapeptide	Very short (minutes)	A pineal-derived tetrapeptide best known for telomerase upregulation and pineal-gland melatonin restoration in long-running rodent and human studies
Thymalin	Thymic polypeptide extract	Variable	A complex of low-molecular-weight thymic polypeptides used in Russian clinical research for decades — immunomodulation, anti-aging, and supportive care in chronic disease
MOTS-c	Mitochondrially-encoded peptide	Hours; tissue-distributed	A 16-amino-acid peptide encoded within mitochondrial DNA — discovered in 2015 and shown to regulate metabolic homeostasis, AMPK signalling, and insulin sensitivity
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression

Frequently Asked Questions

When in life should I start CJC-1295 + Ipamorelin Blend?

Most longevity-relevant peptides have evidence bases centred on mid-life and later. Earlier use is theoretically reasonable for users with documented age-related markers (elevated inflammation, accelerated epigenetic age) or for compounds whose mechanism is preventative. Below age 35 the benefit for most longevity peptides is theoretical and warrants compound-specific consideration.

Best stack pairing for longevity?

Layered protocols cover multiple hallmarks of aging simultaneously: pineal/telomere (epithalon), thymic/immune (thymalin), mitochondrial (MOTS-c, NAD+), ECM and gene expression (GHK-Cu), and metabolic flexibility (metformin-class or GLP-1-class as appropriate). CJC-1295 + Ipamorelin Blend contributes to its specific hallmark layer in this multi-component framework.

Does CJC-1295 + Ipamorelin Blend actually extend lifespan?

Direct lifespan extension in humans cannot be inferred from current data for any peptide compound. The relevant question is whether CJC-1295 + Ipamorelin Blend measurably moves healthspan-relevant biomarkers — epigenetic age, telomere length, inflammatory panels, metabolic flexibility — in the direction of younger phenotypes. Some compounds in this class have measurable effects on these markers; the lifespan extrapolation remains inferential.

Does CJC-1295 + Ipamorelin Blend interact with rapamycin, metformin, or other longevity stacks?

Most peptide compounds are compatible with the standard longevity small-molecule stack (rapamycin, metformin, NAD precursors, senolytics in pulsed protocols). Interactions where present are typically additive rather than competitive. Verify case-specifically with a longevity-informed clinician.

Is CJC-1295 + Ipamorelin Blend safe during pregnancy or breastfeeding?

CJC-1295 + Ipamorelin Blend, like most non-approved peptide therapeutics, does not have safety data supporting use during pregnancy or lactation. The default position is contraindication during pregnancy, lactation, and active conception, with discontinuation at least 2–3 cycles before planned conception. Approved indications (where they exist) may have specific guidance — verify with the prescribing physician.

What is the standard dosing protocol for CJC-1295 + Ipamorelin Blend?

Conventional CJC-1295 + Ipamorelin Blend dosing is 100 mcg CJC + 200 mcg ipamorelin 1-3x daily subq via subq. For healthspan and biological-age use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

Clinical Protocol

Start a CJC-1295 + Ipamorelin Blend Protocol

Alukard provides physician-supervised longevity protocols with GMP-certified CJC-1295 + Ipamorelin Blend and GMP-certified compounds with biological age testing and healthspan markers.

Get Protocol

Quick Facts

Molecular weight: Variable
Half-life: Mixed
WADA: Both components banned (S2)
FDA: Unapproved
Research: Off-label clinical use; mechanistic studies

Stack Partners

Epithalon

Thymalin

NAD+

MOTS-c

GHK-Cu

Research Note

All longevity / hallmarks of aging applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for CJC-1295 + Ipamorelin Blend unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised longevity protocols

Start Your Longevity / Hallmarks of Aging Protocol for CJC-1295 + Ipamorelin Blend

Alukard provides physician-supervised longevity protocols with GMP-certified compounds with biological age testing and healthspan markers.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised